| Hypertensive disease
Bystolic vs Epaned
Side-by-side clinical, coverage, and cost comparison for hypertensive disease.Deep comparison between: Bystolic vs Epaned with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEpaned has a higher rate of injection site reactions vs Bystolic based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Epaned but not Bystolic, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Bystolic
Epaned
At A Glance
Oral
Daily
Selective beta-1 blocker
Oral
Once or twice daily
ACE inhibitor
Indications
- Hypertensive disease
- Hypertensive disease
- Heart failure
- Ventricular Dysfunction, Left
Dosing
Hypertensive disease Start at 5 mg once daily, with or without food; increase at 2-week intervals up to 40 mg. In severe renal impairment (ClCr <30 mL/min), start at 2.5 mg once daily. In moderate hepatic impairment (Child-Pugh Class B), start at 2.5 mg once daily.
Hypertensive disease Adults: 5 mg once daily orally, titrated up to 40 mg daily; pediatric patients >1 month: 0.08 mg/kg (up to 5 mg) once daily; renal impairment (GFR <=30 mL/min) or dialysis: initial dose 2.5 mg daily.
Heart failure 2.5 mg twice daily orally, titrated up to 20 mg twice daily as tolerated; usually given in combination with diuretics and digitalis.
Ventricular Dysfunction, Left 2.5 mg twice daily orally, titrated up to 10 mg twice daily as tolerated.
Contraindications
- Severe bradycardia
- Heart block greater than first degree
- Cardiogenic shock
- Decompensated cardiac failure
- Sick sinus syndrome (unless a permanent pacemaker is in place)
- Severe hepatic impairment (Child-Pugh >B)
- Hypersensitivity to any component of this product
- History of angioedema or hypersensitivity related to previous ACE inhibitor treatment
- Hereditary or idiopathic angioedema
- Co-administration of aliskiren in patients with diabetes
- Combination with a neprilysin inhibitor (e.g., sacubitril), or within 36 hours of switching to or from sacubitril/valsartan
Adverse Reactions
Most common (>=1%) Headache, fatigue, diarrhea, nausea, dizziness, bradycardia, chest pain, peripheral edema, insomnia, dyspnea, rash
Postmarketing Abnormal hepatic function, acute pulmonary edema, acute renal failure, atrioventricular block (second and third degree), bronchospasm, erectile dysfunction, hypersensitivity (urticaria, allergic vasculitis, angioedema), hypotension, myocardial infarction, pruritus, psoriasis, Raynaud's phenomenon, peripheral ischemia/claudication, somnolence, syncope, thrombocytopenia, vertigo, vomiting
Most common (>1%) Fatigue, orthostatic effects, asthenia, cough, rash; in heart failure patients: hypotension, dizziness.
Serious Angioedema, hypotension, hepatic failure, renal impairment, hyperkalemia, cardiac arrest, myocardial infarction, cerebrovascular accident, neutropenia, thrombocytopenia, bone marrow depression.
Postmarketing Pancreatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome, pemphigus, eosinophilic pneumonitis, pulmonary infiltrates, gynecomastia.
Pharmacology
Nebivolol is a beta-adrenergic receptor blocking agent; at doses <=10 mg in extensive metabolizers it is preferentially beta1-selective, while in poor metabolizers or at higher doses it inhibits both beta1- and beta2-adrenergic receptors, lacking intrinsic sympathomimetic and membrane-stabilizing activity at therapeutically relevant concentrations.
ACE inhibitor; enalapril is hydrolyzed to enalaprilat, which inhibits angiotensin-converting enzyme, suppressing the renin-angiotensin-aldosterone system and thereby reducing plasma angiotensin II, vasopressor activity, and aldosterone secretion.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Bystolic
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (4/12) · Qty limit (1/12)
Epaned
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Bystolic
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Epaned
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Bystolic
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Epaned
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Bystolic.
No savings programs available for Epaned.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BystolicView full Bystolic profile
EpanedView full Epaned profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.